These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 31829087

  • 21. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C, Schwarz EI, Saxer S, Lichtblau M, Ulrich S.
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [Abstract] [Full Text] [Related]

  • 22. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
    Badagliacca R, D'Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, Casu G, Confalonieri M, Corda M, Correale M, D'Agostino C, De Michele L, Galgano G, Greco A, Lombardi C, Manzi G, Mercurio V, Mulè M, Paciocco G, Papa S, Romeo E, Scelsi L, Stolfo D, Vitulo P, Naeije R, Vizza CD.
    Am J Respir Crit Care Med; 2021 Feb 15; 203(4):484-492. PubMed ID: 32857597
    [Abstract] [Full Text] [Related]

  • 23. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
    Mandras S, Kovacs G, Olschewski H, Broderick M, Nelsen A, Shen E, Champion H.
    J Cardiovasc Pharmacol Ther; 2021 Sep 15; 26(5):453-462. PubMed ID: 33836637
    [Abstract] [Full Text] [Related]

  • 24. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C, Chen J.
    Cochrane Database Syst Rev; 2006 Jul 19; (3):CD004434. PubMed ID: 16856046
    [Abstract] [Full Text] [Related]

  • 25. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
    Zheng YG, Ma H, Hu EC, Liu G, Chen G, Xiong CM.
    Pulm Pharmacol Ther; 2014 Dec 19; 29(2):241-9. PubMed ID: 25173912
    [Abstract] [Full Text] [Related]

  • 26. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.
    Thakkar V, Nikpour M, Stevens WM, Proudman SM.
    Intern Med J; 2015 Mar 19; 45(3):248-54. PubMed ID: 25735576
    [Abstract] [Full Text] [Related]

  • 27. Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis.
    Didriksen H, Molberg Ø, Fretheim H, Gude E, Jordan S, Brunborg C, Palchevskiy V, Garen T, Midtvedt Ø, Andreassen AK, Distler O, Belperio J, Hoffmann-Vold AM.
    Arthritis Rheumatol; 2021 Jul 19; 73(7):1277-1287. PubMed ID: 33497027
    [Abstract] [Full Text] [Related]

  • 28. Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.
    Hoenicka M, Golovchenko S, Englert L, Spaeth M, Shoshiashvili L, Großer C, Hofmann HS, Ried M.
    Cardiovasc Drugs Ther; 2019 Jun 19; 33(3):287-295. PubMed ID: 30826900
    [Abstract] [Full Text] [Related]

  • 29. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C, Praino E, Nivuori M, di Serio F, Lapadula G, Iannone F.
    Int J Rheum Dis; 2017 Jan 19; 20(1):90-96. PubMed ID: 26218502
    [Abstract] [Full Text] [Related]

  • 30. Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension.
    Tanaka S, Uchida S, Hakamata A, Miyakawa S, Odagiri K, Inui N, Watanabe H, Namiki N.
    Pharmazie; 2020 Jun 01; 75(6):236-239. PubMed ID: 32539916
    [Abstract] [Full Text] [Related]

  • 31. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
    McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V.
    Rheumatology (Oxford); 2009 Jun 01; 48 Suppl 3():iii25-31. PubMed ID: 19487219
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL, Chen XY, Li JR, Su SW, Ding T, Shi CX, Jiang YF, Zhu ZN.
    Chest; 2016 Aug 01; 150(2):353-66. PubMed ID: 27048870
    [Abstract] [Full Text] [Related]

  • 33. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management.
    Ramirez A, Varga J.
    Treat Respir Med; 2004 Aug 01; 3(6):339-52. PubMed ID: 15658881
    [Abstract] [Full Text] [Related]

  • 34. Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.
    Kirtania L, Maiti R, Srinivasan A, Mishra A.
    Clin Drug Investig; 2019 Nov 01; 39(11):1031-1044. PubMed ID: 31420854
    [Abstract] [Full Text] [Related]

  • 35. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C, Cheng J.
    Cochrane Database Syst Rev; 2005 Jan 25; (1):CD004434. PubMed ID: 15674947
    [Abstract] [Full Text] [Related]

  • 36. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M, Becker M, Riedlinger A, Siegert E, Drömann D, Yu X, Petersen F, Riemekasten G.
    Clin Rheumatol; 2017 Feb 25; 36(2):381-390. PubMed ID: 28028682
    [Abstract] [Full Text] [Related]

  • 37. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
    Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A, Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators.
    Ann Rheum Dis; 2012 Feb 25; 71(2):249-52. PubMed ID: 21998119
    [Abstract] [Full Text] [Related]

  • 38. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
    Ramjug S, Hussain N, Hurdman J, Billings C, Charalampopoulos A, Elliot CA, Kiely DG, Sabroe I, Rajaram S, Swift AJ, Condliffe R.
    Chest; 2017 Jul 25; 152(1):92-102. PubMed ID: 28223154
    [Abstract] [Full Text] [Related]

  • 39. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E, Ohnesorge J, Benjamin N, Burhenne J, Enderle Y, Egenlauf B, Fischer C, Harutyunova S, Huppertz A, Klose H, Haefeli WE.
    Respiration; 2017 Jul 25; 94(1):26-37. PubMed ID: 28494463
    [Abstract] [Full Text] [Related]

  • 40. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
    Volkmann ER, Saggar R, Khanna D, Torres B, Flora A, Yoder L, Clements PJ, Elashoff RM, Ross DJ, Agrawal H, Borazan N, Furst DE, Saggar R.
    Arthritis Rheumatol; 2014 Jul 25; 66(7):1900-8. PubMed ID: 24729406
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.